Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Novartis
Memorial Sloan Kettering Cancer Center
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Genmab
Janssen Pharmaceutical K.K.
Genmab
Genmab
Bristol-Myers Squibb
Nationwide Children's Hospital
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Daiichi Sankyo
Acerta Pharma BV
Dana-Farber Cancer Institute
Galapagos NV
M.D. Anderson Cancer Center
Allogene Therapeutics
Astellas Pharma Inc
Ohio State University Comprehensive Cancer Center
Servier
Faron Pharmaceuticals Ltd
City of Hope Medical Center
Celgene
Seattle Children's Hospital
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Acerta Pharma BV
University of Southern California
AstraZeneca
AstraZeneca
Ohio State University Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
ImCheck Therapeutics
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
BeOne Medicines
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Taiho Oncology, Inc.
Memorial Sloan Kettering Cancer Center
Bambino Gesù Hospital and Research Institute
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center